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Abstract  20 
Drug repositioning and repurposing can enhance traditional drug development efforts and could 21 
accelerate the identification of new treatments for individuals with Alzheimer disease (AD) dementia 22 
and mild cognitive impairment. Transcriptional profiling offers a new and highly efficient approach 23 
to the identification of novel candidates for repositioning and repurposing. In the future, novel AD 24 
transcriptional signatures from cells isolated at early stages of disease, or from human neurons or 25 
microglia that carry mutations that increase risk of AD, might be used as probes to identify 26 
additional candidate drugs. Phase II trials assessing repurposed agents must consider the best target 27 
population for a specific candidate therapy as well as the mechanism of action of the treatment. In 28 
this Review, we highlight promising compounds to prioritise for clinical trials in individuals with AD, 29 
and discuss the value of Delphi consensus methodology and evidence-based reviews to inform this 30 
prioritization process. We also describe emerging work, focussing on the potential value of transcript 31 






[H1] Introduction 36 
The growing global health challenge posed by dementia needs to be addressed. Currently, more 37 
than 40 million people have Alzheimer disease (AD) worldwide and this number is expected to 38 
increase to more than 100 million by 20501. In addition, estimates indicate that at least 15% of 39 
people aged 60 or above have mild cognitive impairment (MCI), and that 8–15% of these individuals 40 
will progress to dementia each year, most commonly to AD2. AD is a devastating, progressive 41 
neurodegenerative disease that has a massive personal and financial impact on individuals, families 42 
and society. The estimated annual cost of dementia worldwide is US$818 billion, which is predicted 43 
to increase to US$1 trillion within this decade1. In the last 20 years only two new pharmacological 44 
therapies have become available for the treatment of AD. One of the treatments, memantine, has 45 
been licensed for the treatment of AD globally, whereas the other, oligomannate, is only licensed in 46 
China. Importantly, no pharmacological treatments have been licensed for use in individuals with 47 
MCI.  48 
The core pathological substrates of AD in the brain are amyloid plaques and neurofibrilliary tangles; 49 
the latter involve the hyper-phosphorylation of tau3. The importance of other potential mechanisms, 50 
including neuro-inflammation, protein misfolding, mitochondrial dysfunction and clearance of 51 
abnormal proteins, in the pathophysiology of AD has become increasingly apparent4. Despite a 52 
number of controversies regarding the role of amyloid in the pathogenesis of AD, including the 53 
question of whether neuronal death is driven by amyloid plaques or soluble amyloid and oligomers5, 54 
the vast majority of treatments evaluated in clinical trials have focussed on amyloid-related targets. 55 
The last decade has seen a number of high profile unsuccessful randomised clinical trials (RCTs) of 56 
amyloid-focussed treatments, for example the anti-amyloid immunotherapy Solanezumab6 and the 57 
β-secretase inhibitor Verubecestat 7. A recent review of the NIH clinical trial registry identified only 58 
29 pharmacological or biological treatments in ongoing phase II or phase III trials for disease 59 
modification in AD or MCI8. This number is 40-fold less than the number of ongoing RCTs for cancer8 60 
and the number of RCTs of disease-modifying therapies for AD has not substantially increased since 61 
20129. Despite the enormous potential value of an effective disease-modifying therapy for AD or 62 
MCI, this area of research is considered to be high risk by the pharmaceutical industry, particularly as 63 
a result of low clinical trial success rates, and a number of global pharmaceutical companies have 64 
withdrawn investment from this therapeutic area10. Multiple factors could be responsible for the 65 
failed trials of disease-modifying therapies for AD, for example, the use of sub-optimal treatments 66 
and targets, a narrow range of targets, and methodological issues with the trials (Box 1). 67 
Furthermore, owing to the low sensitivity of clinical and neuropsychological outcome measures, 68 
nearly 500 participants per treatment arm are needed for adequately powered phase II trials in 69 
 
 
individuals with MCI, which means that many phase II trials in individuals with this condition are 70 
significantly underpowered and the results are difficult to interpret11.  71 
 72 
Emerging results from trials of the amyloid-targeting antibody aducanumab indicated that, in one of 73 
the two completed phase III trials, participants receiving aducanumab showed a statistically 74 
significant improvement in cognition and function compared with participants receiving placebo, 75 
particularly in the groups of participants carrying APOE ε412. The data from the other phase III trial 76 
were less clear, although some indication of benefit in participants exposed to higher doses was 77 
reported12. The results of these trials are not yet fully in the public domain and have not been 78 
subjected to peer review, so interpretation needs to be cautious. Therapies that focus on other key 79 
treatment targets such as tau and neuro-inflammation are at an earlier stage of development than 80 
aducanumab, but the preclinical data is promising13. These encouraging results might have a positive 81 
impact on AD drug discovery, for example, by attracting increased investment from the 82 
pharmaceutical industry. However, complementing traditional drug discovery with a broader range 83 
of approaches, such as drug repositioning and repurposing, will maximize drug development efforts. 84 
We used a systematic review of the literature and a Delphi consensus approach to highlight existing 85 
compounds that we feel should be prioritised for clinical trials in individuals with AD. In this Review, 86 
we present the results of that Delphi consensus and describe the evidence underlying the consensus 87 
prioritisation. We then describe emerging work, focussing on the potential value of transcript 88 
signatures as a cost-effective approach to identify novel candidates for repositioning. 89 
 90 
[H1] Drug repositioning and repurposing 91 
Drug repositioning occurs within the biopharma industry during drug development and refers to the 92 
development of an agent for an indication other than the indication it was originally intended for. 93 
This new indication is prioritised during the development process and before approval. In contrast, 94 
drug repurposing is defined as “the application of established drug compounds to new therapeutic 95 
indications”14 and offers a route to drug development that is accessible to academic institutions, 96 
government and research council programs, charities and not-for-profit organizations, thus 97 
complementing the work of pharmaceutical and biotechnology companies. Repositioning and 98 
repurposing offer an attractive way of enhancing traditional drug development and accelerating the 99 
arrival of new treatments for AD dementia and MCI in the clinic. Phase II trials assessing repurposed 100 
agents must consider the best target population for a specific candidate therapy as well as the 101 




Drug repurposing has enabled the identification of successful therapies for many diseases ranging 104 
from cancer15 to Parkinson disease16. One important advantage of this approach is that the safety of 105 
the candidate compound has already been established, which removes the need for further pre-106 
clinical safety testing, chemical optimization or toxicology studies, and thus substantially reduces the 107 
time and cost involved in progressing the potential treatment into clinical trials. Marketed drugs are 108 
likely to have a reasonable safety database derived from previous registrational programmes, post-109 
marketing experience and safety surveillance. In many cases, understanding this safety profile offers 110 
a solid ‘freedom to operate’ when repurposing the drug in a relatively fragile population, such as 111 
individuals with AD. Drug repurposing might also offer the further key advantage of bypassing the 112 
early preclinical, phase II and even phase IIa trials, all of which are time consuming and represent 113 
periods of relatively high drug attrition. In addition, many of the costs of drug development that are 114 
not always readily recognized, such as those associated with formulation optimisation, 115 
manufacturing development, and drug–drug interaction studies, have been addressed by the 116 
biopharmaceutical company that originally developed the drug. The estimated cost of developing a 117 
drug to the point of approval is US$5.6 billion17, but these extreme costs can be lower in 118 
programmes that focus on repurposed agents. Furthermore, for repurposed agents, clinical evidence 119 
of potential efficacy can be derived from existing pathophysiological observations, epidemiological 120 
cohort studies, open-treatment studies and preliminary clinical trials. This clinical information 121 
provides an important added dimension to the available evidence, particularly given the limitations 122 
of animal models.  123 
 124 
Candidates for drug repurposing can be selected via a number of different routes, one of which is 125 
the use of large datasets to detect drug-associated patient outcomes that would otherwise have not 126 
been identified18. An alternative route is hypothesis-driven repurposing, which combines 127 
information about the disease of interest and the properties and targets of existing drugs for other 128 
conditions to identify potential candidates9. Similarly, high-throughput screening using in vitro 129 
models designed to assess the effects of compounds on known target mechanisms, such as amyloid 130 
toxicity, can be used19. A novel method is the use of disease-associated transcriptional signatures as 131 
a tool for identifying candidate therapies20. Another approach is to combine several of the above 132 
sources of information by manually reviewing the existing literature to identify candidates for 133 
repurposing. The challenge is that the kind of evidence available often varies among different 134 
compounds, for example, strong in vitro or in vivo evidence might exist for some candidates, 135 
whereas strong epidemiological evidence might exist for others. In addition, any identified 136 
treatment has to also be suitable for the target population, which for AD is older individuals with 137 
dementia. One way of addressing this challenge is to combine systematic review of the evidence 138 
 
 
with rigorous expert interpretation and consensus using methodologies such as the Delphi 139 
consensus approach, which is a standardized approach to achieving expert consensus based on a 140 
standardized review of the evidence and serial re-rating of priorities by a panel of experts.  141 
 142 
[H1] The Delphi consensus process  143 
In writing this Review we combined available evidence from the repurposing routes described in the 144 
previous section with the aim of identifying the best candidate compounds for the treatment of AD 145 
or MCI. This process involved a comprehensive assessment of the published literature, a systematic 146 
evaluation of the evidence and a formal Delphi consensus process involving an expert panel. The 147 
Delphi panel had 12 members, with expertise from the pharmaceutical industry, academia or drug 148 
development funding within the charity sector, including the authors of this Review (with the 149 
exception of G.W., P.D., A.C. & J.S.) and 3 additional panel members who represented patient 150 
organizations (see acknowledgements section). Each panel member was asked to nominate up to 151 
ten candidate compounds for further consideration. A full systematic review of the literature was 152 
prepared for all five candidate compounds that were identified by at least three members of the 153 
panel. The members of the panel then ranked these five drug candidates in order of priority on the 154 
basis of the strength of evidence. The key factors used for this ranking included the mechanism and 155 
efficiency of brain penetration, the safety profile of the compound and whether or not the dosage of 156 
the drug used in preclinical studies was equivalent to the safe human dosage. The prioritization 157 
ratings of each panel member were shared with the panel at a face-to-face meeting and a second 158 
prioritization exercise was undertaken by e-mail. The prioritization was then finalized at a further 159 
face-to-face meeting of the panel. This methodology was designed to update the systematic review 160 
and Delphi consensus published in 2012 in Nature Reviews Drug Discovery9. As the aim of this 161 
second Delphi consensus was to identify new candidate compounds, priority candidates from the 162 
2012 census were excluded, but candidates not prioritised by the 2012 consensus were eligible if 163 
new evidence had emerged.  164 
 165 
[H1] Update on existing priority compounds 166 
The 2012 Delphi consensus9 prioritised five classes of compounds for repurposing as treatments for 167 
AD: tetracycline antibiotics, calcium channel blockers, angiotensin receptor blockers (ARBs), 168 
glucagon-like peptide 1 (GLP1) analogues and retinoid therapy. With the exception of retinoid 169 
therapy, all of the prioritised classes of compounds have now been taken into clinical trials. Trials of 170 
the tetracycline antibiotic minocycline21, the calcium channel blocker nilvadipine22 and the ARB 171 
losartan23 have been completed and did not find any significant benefits of treatment on the 172 




[H2] Tetracycline antibiotics  175 
The RCT of minocycline21 was a 3-arm 24-month trial that compared the effects of either 400 mg 176 
minocycline per day, 200 mg minocycline per day, or placebo, in a total of 554 participants with mild 177 
AD and a Mini Mental Status Examination (MMSE) score of ≥24. The two groups of participants who 178 
received the minocycline treatment were combined for the data analysis. In this combined group, 179 
the change in mean MMSE, the primary outcome measure, over 24 months was only 0.1 points less 180 
than in the group that received placebo. No difference in the change in ability to perform activities 181 
of daily living over the 24 months was detected between the two groups. This was a pragmatic, but 182 
well-designed study, and provides a clear negative result, which suggests that further trials of 183 
minocycline for the treatment of AD are not warranted.  184 
 185 
[H2] Calcium channel blockers  186 
Nilvadipine (8 mg per day) was evaluated in an 18-month double-blind RCT in 511 participants, of 187 
whom 253 received nilvadipine and 258 received placebo22. The participants were over the age of 50 188 
and had an MMSE score between 12 and 27, thus meeting the National Institute of Neurologic and 189 
Communicative Disorders and Stroke – Alzheimer’s Disease and Related Disorders Association 190 
(NINCDS-ADRDA) criteria for probable AD24. The primary outcome measure was a change in 191 
Alzheimer’s Disease Assessment Scale – cognitive subscale (ADAS–COG) score; however, only a 0.21-192 
point non-significant difference in average ADAS–COG was observed between the two treatment 193 
groups over 18 months. For context, studies of cholinesterase inhibitors have reported differences of 194 
> 2 points on the ADAS–COG score between groups of participants receiving treatment and groups 195 
of participants receiving placebo25 and this would usually be regarded as the minimum clinically 196 
meaningful degree of change26. No benefit of treatment with nilvadipine was detected with the co-197 
primary outcome measure (Clinical Dementia Rating – sum of boxes), or on any of the secondary or 198 
exploratory outcome measures. This trial was well-designed and adequately powered and the 199 
absence of any significant differences between groups is clearly a negative result, and plans for 200 
further studies of nilvadapine for the treatment of AD have not been reported. 201 
 202 
 [H2] Angiotensin receptor blockers 203 
In a preliminary study, 20 participants with probable AD and essential hypertension were randomly 204 
assigned to receive either the ARB telmisartan (10 participants, 40–80 mg per day) or the calcium 205 
channel blocker amlodipine (10 participants, 5–10 mg per day) for 6 months27. The group of 206 
participants who received telmisartan had increased regional cerebral blood flow in the right 207 
supramarginal gyrus, superior parietal lobule, cuneus, and lingual gyrus compared with the group of 208 
 
 
participants that received amlodipine. No differences in cognition were observed between the two 209 
groups, but the study was very underpowered for detecting neuropsychological outcomes. More 210 
recently, in an RCT of the ARB losartan, 211 participants with mild or moderate AD were randomly 211 
assigned to receive either 100mg losartan or placebo once daily for 12 months23. Preliminary results 212 
from the trial were presented at the Clinical Trials on Alzheimer’s Disease (CTAD) conference in 213 
2019. No significant reduction in the rate of cortical atrophy, which was the primary outcome 214 
measure, was observed in the participants receiving losartan compared with those receiving 215 
placebo, and the other clinical and cognitive outcomes measures showed no indication of 216 
improvement associated with losartan treatment. Although the trial was underpowered for 217 
detecting changes in clinical outcomes, the absence of any trends towards improvement in the 218 
treatment group was disappointing23. 219 
 220 
Despite these negative clinical trial results, a solid body of in vitro and in vivo work supports the 221 
potential utility of ARBs as a treatment for AD28-40. In vitro work has identified multiple effects of 222 
centrally acting angiotensin II, including vasoconstriction, mitochondrial dysfunction, inhibition of 223 
acetylcholine release, increased production of angiotensin IV and release of inflammatory 224 
mediators28-30, that suggest ARBs could be suited to repurposing for AD. Many commonly used ARBs, 225 
such as candesartan and losartan, have known blood–brain barrier penetration properties and have 226 
been shown to attenuate the central effects of angiotensin II in animal studies31. For example, in one 227 
study treatment with the ARB valsartan was associated with reduced amyloid-β aggregation in 228 
vitro32, and improvements in behavioural tests of cognitive performance and reductions in amyloid 229 
pathology in a mouse model of AD32. In other studies of mouse models of AD, animals treated with 230 
ARBs showed reduced brain levels of total amyloid or amyloid-β aggregation, improvements in 231 
cognition and reduced neuroinflammation compared with animals treated with saline33-37. Studies of 232 
ARBs in Sprague Dawley rats have produced contradictory results, with some studies reporting an 233 
ARB-associated decrease in tau phosphorylation and some studies reporting an ARB-associated 234 
increase in tau phosphorylation38-40. 235 
 236 
Some epidemiological evidence also supports use of ARBs for the treatment of AD. A large 4-year 237 
study of the medical records of 800,000 adults over 65 reported an almost 50% reduction in incident 238 
AD in individuals receiving ARBs compared with individuals receiving other cardiovascular 239 
treatments. The ONTARGET trial included 16,000 participants with hypertension and significantly 240 
fewer participants declined to an MMSE score <18 in the group receiving the ARB telmisartan than in 241 
the group receiving the ACE inhibitor ramipril41. However, this finding was not replicated in the 242 
parallel TRANSCEND trial in 5,000 participants with hypertension, which compared telmisartan with 243 
 
 
placebo41, nor in the SCOPE trial in nearly 5,000 participants with hypertension, which compared the 244 
ARB candesartan with placebo. However, a sub-group analysis in participants from the SCOPE trial 245 
with pre-treatment MMSE scores of 24–28 showed a modest benefit of treatment on cognitive 246 
ability42.  247 
 248 
The overall evidence for the use of ARBs to treat AD is mixed, and the absence of any benefits in the 249 
RCT of losartan is disappointing. However, the evidence reviewed in this section focuses on specific 250 
treatment mechanisms that are related directly to actions on the rennin angiotensin system. These 251 
observations must be interpreted in the context of strong epidemiological evidence indicating that 252 
hypertension is a risk factor for AD dementia43 and the results of the recent SPRINT MIND trial, 253 
which demonstrated a significant reduction in the of MCI and probable AD dementia in participants 254 
receiving intensive anti-hypertensive management (target systolic blood pressure <120 mm hg) 255 
compared with the usual anti-hypertensive management (target systolic blood pressure <140 mm 256 
hg)44. The potential overall benefits of blood pressure reduction for heart and brain health should 257 
also be considered. Indeed, RCTs of candesartan and telmisartan in individuals with or at risk of AD 258 
are ongoing, and we should not discount ARBs as a potential treatment until the results of these 259 
trials are reported45,46,47. 260 
 261 
 262 
[H2] GLP1 analogues  263 
The emerging evidence base for the use of GLP1 analogues to treat AD is more encouraging than 264 
that of the other compounds prioritised by the 2012 Delphi consensus9. GLP1 analogues were 265 
prioritised on the basis of several in vivo studies in mouse models of AD that demonstrated an effect 266 
of this treatment on amyloid and tau pathologies48-51as well as oxidative stress, apoptosis, synaptic 267 
plasticity and other core neuronal functions49, 51-57. More recently, this work was extended by a study 268 
of the GLP1 analogue liraglutide58. In this study, treatment of APP–PS1 mice (which carry AD-269 
associated mutations in APP and presenilin) with liraglutide from the age of 2 months attenuated 270 
the development of progressive AD-related pathological changes, such as synapse loss, synaptic 271 
plasticity and amyloid plaques. Indeed, treatment with liraglutide has consistently been associated 272 
with improvements in cognition and memory in animal models of AD58-61.  273 
 274 
Three randomised, double-blind, multicentre, placebo-controlled trials examining of the 275 
cardiovascular effects of liraglutide or semaglutide also included the development of dementia as an 276 
exploratory outcome. A total of 15,820 participants were included in the 3 trials and the median 277 
follow-up period was 3.6 years. Across the 3 trials, 15 participants who received a GLP1 analogue 278 
 
 
and 32 participants who received placebo developed dementia, with an estimated hazard ratio of 279 
0.47 (95% CI 0.25; 0.86) in favour of the GLP1 analogue treatment (C.B., unpublished work). This 280 
analysis is exploratory, and the frequency of incident dementia was modest. A post-hoc analysis of 281 
the data from a RCT of another GLP-1 analogue, dulaglutide, for the prevention of adverse 282 
cardiovascular outcomes in people with diabetes, also reported a significant reduction in incident 283 
dementia in participants treated with dulaglutide compared with participants receiving placebo62. 284 
The findings of these RCTs need to be interpreted cautiously as they are based on post-hoc analyses, 285 
but are consistent with a role for GLP1 analogue treatment in preventing the development of 286 
dementia. 287 
Several more recent studies of GLP1 analogues in individuals with AD are underway or have been 288 
completed. A preliminary randomized, placebo-controlled clinical 20F-fluorodeoxyglucose (FDG)-PET 289 
study in 38 individuals with AD demonstrated that, compared with placebo, 6 months of treatment 290 
with liraglutide at a dose of 1.8 mg per day by subcutaneous injection prevented a decline in glucose 291 
metabolism in the brain63. Glucose metabolism is used as a marker of brain activity, and a lack of 292 
decline in glucose metabolism is usually taken to indicate preservation of biological brain function. 293 
Further analysis indicated that the underlying mechanism for this effect is an increase in blood–brain 294 
glucose transfer capacity and that, in the group of participants who received liraglutide, transfer 295 
capacity was the same as in healthy controls. A larger phase II RCT involving 204 participants with AD 296 
was completed in 201964. The results of an 18-month pilot double blind placebo controlled RCT of 297 
exenatide have also been reported65. The study, which included only 21 participants, found that the 298 
exenatide was well-tolerated, although an expected increase in nausea and decreased appetite was 299 
observed in the group that received the drug compared with the group that received placebo. The 300 
study found no significant difference in clinical, cognitive, neuroimaging or cerebrospinal fluid (CSF) 301 
measures between the two groups; however, given the very limited power of this study, these 302 
observations cannot be meaningfully interpreted. The levels of Aβ42 in plasma extracellular neuronal 303 
vesicles were lower in participants receiving exenatide than in participants receiving placebo, which 304 
is an interesting result65.  305 
 306 
The results of these studies of GLP-1 analogues are promising and provide increasing evidence that 307 
these drugs might prevent incident dementia in people with diabetes. A broader question is the 308 
potential utility of GLP-1 analogues for the treatment of MCI due to AD or AD outside the context of 309 
diabetes. The pre-clinical studies in this area are encouraging, but further trials are needed and the 310 
results of the ongoing Evaluating Liraglutide in Alzheimer's Disease (ELAD) trial are eagerly awaited. 311 
 312 
[H1] New priority compounds 313 
 
 
During the 2018–2019 Delphi process a total of five compounds (or classes of compounds) were 314 
nominated for further consideration by at least three members of the panel. These compounds were 315 
ACE inhibitors, anti-viral drugs, disease-modifying agents for rheumatoid arthritis, fasudil and 316 
phenserine (Table 1). Following several rounds of prioritisation, the panel came to a clear consensus 317 
that the three highest priority candidates for repurposing in AD were fasudil, anti-viral drugs and 318 
phenserine. Each of these compounds achieved the same prioritisation rating and there was no 319 
specific prioritization within the three identified candidates.  320 
 321 
 [H2] Fasudil 322 
Fasudil, a selective inhibitor of Rho Kinase (ROCK) 1 and 2, is a potent vasodilator, particularly of the 323 
cerebral vasculature66, and is approved in Japan and China for the treatment of cerebral vasospasm 324 
following subarachnoid haemorrhage67. Fasudil was first suggested as a potential treatment for AD 325 
in 2009 when a study found that administration of the compound was associated with protection 326 
against age-related memory impairment in rats68. In a subsequent study, fasudil was mixed into 327 
artificial CSF administered directly into the brain in the APP–PS1 mouse model of AD. The aberrant 328 
dendritic arborisation phenotype of this mouse model was reduced in mice receiving fasudil 329 
compared with mice receiving artificial CSF alone69. Fasudil administration was also associated with 330 
protection against hippocampal neurodegeneration induced by intracerebroventricular injection of 331 
Aβ 1–42 in rats. The authors reported increased IL-1β, increased tumor necrosis factor alpha (TNF-α) 332 
production, and increased activation of NF-κB in rats receiving fasudil treatment compared with rats 333 
receiving placebo and postulated that the protection against amyloid might be related to 334 
suppression of inflammatory responses70. More recent work using cell culture and several different 335 
transgenic mouse models of AD suggests that fasudil can protect against synaptic loss and cognitive 336 
impairment mediated by Aβ through the Dkk1-driven Wnt–PCP pathway71-72. Fasudil, delivered 337 
intraperitoneally, was also associated with reduced brain amyloid burden in the 3xAD-TG mouse 338 
model of AD73. 339 
 340 
Fourteen randomized placebo-controlled trials of fasudil were identified in the literature74. These 341 
trials included a combined total of >500 participants with a range of indications from coronary heart 342 
disease to pulmonary hypertension. Fasudil was administered at doses of 60–240 mg per day, and 343 
most trials reported good tolerability with no significant safety concerns. However, one double-344 
blind, placebo-controlled clinical trial of a new extended release formulation of fasudil for 345 
pulmonary arterial hypertension did highlight several safety concerns75. In this trial, 2 out of 12 346 
patients in the active treatment group discontinued the treatment, one because of renal impairment 347 
and the other because of death from heart failure. One small 2-month randomized clinical trial 348 
 
 
conducted in China investigated the efficacy of fasudil for treatment of AD76. In this trial, 106 male 349 
participants with MCI treated with nimodopine were randomly assigned to receive either 30 mg 350 
intravenous fasudil (once per day) or placebo for 2 months. Preliminary results indicate that fasudil 351 
was well tolerated and the group treated with fasudil had significantly higher MMSE scores the than 352 
the group that received placebo. This efficacy data should be interpreted cautiously, but good 353 
tolerability in individuals with MCI is important.  354 
Overall, there is high concordance between the results of different preclinical studies, which suggest 355 
that fasudil targets classical AD neuropathology77 by reducing amyloid burden, and also targets other 356 
pathological mechanisms that contribute to AD, for example, by protecting against inflammation and 357 
synaptic damage77-78. These biochemical and physiological benefits have consistently translated into 358 
cognitive improvement using in vivo AD models70,77-78.  359 
 360 
[H2] Phenserine  361 
Phenserine was initially developed and evaluated as a cholinesterase inhibitor79. However, several 362 
mechanisms exist by which phenserine might reduce neuronal and synaptic loss80, which are 363 
important pathways in AD, traumatic brain injury and other neurodegenerative diseases. The results 364 
of a range of preclinical studies indicate that phenserine suppresses production of IL-1b, reduces 365 
glutamate-induced excitotoxicity, protects against H2O2-induced oxidative toxicity, reduces levels of 366 
Aβ, improves neural precursor cell viability, elevates neurotrophic brain-derived neurotrophic factor, 367 
and inhibits amyloid precursor protein (APP) and α-synuclein synthesis80-83. In particular, the results 368 
of several preclinical studies indicate that phenserine can reduce APP levels in vitro and in vivo 84-88. 369 
Although these potential actions are of interest, more importantly, recent work has suggested that 370 
phenserine might confer significant neuroprotection by inhibiting apoptosis via actions on a pre-371 
programmed cell death pathway83. This hypothesis has been evaluated in several rodent models of 372 
neuronal loss, including the APP–PSEN1 mouse model of AD, a rat model of post-stroke re-perfusion 373 
injury and a weight drop mouse model of traumatic brain injury81-83. In all of these animal studies, 374 
treatment with phenserine was associated with significant reductions in the severity of 375 
neurodegenerative lesions, and decreases in the neuroinflammatory response (via suppression of 376 
the IBA1 and TNF-α pathways) in the hippocampus and/or cortex80,82,83. Phenserine treatment was 377 
also associated with protection against reductions in synaptic density and levels of synaptophysin in 378 
animal models of AD and TBI80-83. The multi-faceted pharmacological action of phenserine as a 379 
neuroprotective agent was an important factor in the prioritisation of this compound by the panel. 380 
In addition, administration of phenserine was associated with improved cognition in rats with 381 




Phenserine has been evaluated in two phase II placebo controlled trials in individuals with mild to 384 
moderate AD79,90. The results of a phase II, 12-week RCT in 164 participants with AD indicated that (-385 
)-phenserine (10–15 mg twice per day) had a favourable safety profile and the group of participants 386 
receiving the drug showed significantly improved cognitive function compared with the group of 387 
participants receiving placebo79. A trend towards improvement in global outcome was observed in 388 
participants who received the higher dose of phenserine79,91, with Cohen’s D effect sizes of 0.3–0.4 389 
for symptomatic benefits, which is similar to the effect sizes seen with other cholinesterase 390 
inhibitors92. A second, smaller RCT randomized 20 participants with mild AD to receive either 391 
phenserine (15mg twice per day) or placebo for 3 months90. Over the subsequent 3 months, the 392 
patients allocated to phenserine continued to receive phenserine treatment while the placebo group 393 
then received donepezil in an open design. At the end of the first 3 months, the group of participants 394 
receiving phenserine had significantly better cognitive function (measured with a composite 395 
neuropsychological test) than the group of participants receiving placebo, and this significant 396 
difference between the two groups was maintained after the group receiving placebo had switched 397 
to donepezil for 3 months90. Although these results are encouraging, they must be interpreted 398 
cautiously given the small sample size of the study. Furthermore, a phase III trial of phenserine was 399 
discontinued early for commercial reasons and did not demonstrate a significant benefit of 400 
treatment on the primary outcome measures, which were ADAS–COG score and clinician's 401 
interview-based impression of change with caregiver input (CIBIC+)93. The results of this phase III 402 
trial have not been published in full, but a press release described non-significant trends towards 403 
improvement with 10 and 15mg doses93. These results are difficult to interpret on the basis of the 404 
preliminary reports, especially as the study was significantly under-powered to detect changes in 405 
cognitive and functional outcomes, with only 284 participants randomized in a 2:2:1 design. In 406 
addition, the dosing regime was probably sub-therapeutic as the compound has a half-life of 5–6 407 
hours, but was only administered twice per day, which led to criticism of the trial design94.  408 
 409 
Overall, the preclinical evidence that phenserine has biological effects that are relevant to the 410 
treatment of AD and other neurodegenerative conditions is strong. These effects include a newly-411 
identified influence on apoptosis. Phenserine also has a good clinical safety profile. Although the 412 
results from phase II studies are encouraging, they need to be interpreted cautiously given the small 413 
sample sizes and short trial durations. Trials of at least 12 months would be needed to identify 414 
disease-modifying effects. The potential of phenserine to combine the symptomatic benefits of a 415 
cholinesterase inhibitor with additional disease-modifying actions is, however, an exciting prospect. 416 
 417 
[H2] Anti-viral drugs   418 
 
 
The potential role of Herpes Simplex virus (HSV) as a risk factor or mediating factor in the 419 
development of AD emerged as a hypothesis in 1991, when HSV 1 was found in an active form in the 420 
brains of a large number of older people95. In 1991, a case–control post-mortem study found an 421 
association between HSV-1 infection and an increased risk of AD96. Little progress was made until the 422 
2000s and 2010s, when further studies identified HSV-1 DNA within amyloid plaques in individuals 423 
with AD97, and provided evidence for a role of HSV-1 in promoting the accumulation of Aβ98-100 and 424 
the abnormal phosphorylation of tau101-103. In 2011, the authors of one study used quantitative 425 
immunocytochemistry in a kidney cell in vitro model to demonstrate that the changes in Aβ and 426 
phospho-tau production, did not occur with the initial entry of the virus into the cell, but were 427 
related to subsequent viral replication104. In vitro, the antivirals acyclovir (the active form of the 428 
prodrug valaciclovir), penciclovir (the active form of the prodrug famciclovir) and foscarnet were 429 
associated with reductions in Aβ and phospho-tau accumulation, as well as levels of HSV-1. 430 
However, foscarnet had a more modest effect than the other two treatments. The accumulation of 431 
phospho-tau was dependent on HSV 1 DNA replication, whereas the accumulation of Aβ was not. 432 
This work was important in highlighting mechanisms that could link HSV1 to the development of AD 433 
pathologies and in identifying candidate therapies. 434 
 435 
More recently, the results of several epidemiological studies have supported the potential value of 436 
anti-viral therapies in the treatment of AD. The authors of one study used Taiwan's National Health 437 
Insurance Research Database (NHIRD) to evaluate the records of 33,448 individuals and identified 438 
8,362 individuals with a newly diagnosed HSV infection as well as 25,086 randomly selected sex-439 
matched and age-matched controls without HSV infections105. The adjusted hazard ratio for the 440 
development of dementia in the participants with HSV-1 relative to the control participants was 2.6 441 
(P < 0.001). Participants with HSV 1 who were treated with anti-herpetic medication had a 442 
significantly lower risk of developing dementia than participants with HSV 1 who were not treated 443 
with these agents. The risk of dementia was lower among participants who used anti-herpetic 444 
medication for ≥30 days than in participants who used these drugs for a shorter duration. Using the 445 
same database, a larger study of the records of 78,410 individuals identified a significant but more 446 
modest increase in the risk of dementia in participants with herpes zoster infection than in 447 
participants without the infection. This study also found that treatment with antiviral therapy 448 
significantly reduced the risk of developing dementia following the diagnosis of herpes zoster 449 
infection106. 450 
 451 
Overall, the evidence from in vitro and post-mortem studies suggests that HSV infection, and 452 
possibly Herpes Zoster virus infection are risk factors for AD. Although the absence of substantive in 453 
 
 
vivo studies is a concern, emerging evidence from large-scale epidemiological studies confirms the 454 
association between risk of cognitive decline and HSV or Herpes Zoster infections. The results of 455 
these epidemiological studies also suggest that this risk can be mitigated by anti-viral therapy. 456 
Therefore, strong arguments exist for exploring the potential benefit of antiviral drugs in individuals 457 
AD. An ongoing phase II study of valaciclovir aims to recruit 130 participants with mild AD107. The 458 
existing evidence suggests that anti-viral compounds might be more effective at diminishing the risk 459 
of AD or delaying the onset of AD in people with MCI, than as a treatment for individuals who have 460 
already developed AD. 461 
In summary, three main classes of compound have emerged from the Delphi consensus process in 462 
2018–2019: fasudil, phenserine and anti-viral drugs. GLP analogues were prioritised by the 2012 463 
Delphi consensus process and remain a high priority candidate for repurposing. The prioritisation of 464 
these compounds is supported by strong packages of preclinical data, most of which include 465 
evidence from a number of different preclinical models. The preclinical data also suggest that each 466 
of these compounds can have an effect on multiple AD-related therapeutic targets in addition to 467 
amyloid. One advantage of repurposed compounds as opposed to newly developed therapeutics, is 468 
that additional data can be gained from epidemiological studies, clinical cohort studies and clinical 469 
trials designed to measure a different outcome. For GLP analogues and anti-viral drugs, clinical 470 
information from epidemiological studies or clinical trials with different primary outcomes support 471 
the potential utility of the treatment as an AD therapeutic. However, information from clinical trials 472 
of any of the prioritised compounds in individuals with MCI or AD is much more limited. As discussed 473 
earlier, several clinical trials of phenserine have been performed, and the results of two phase II 474 
trials suggested that in individuals with AD the treatment was associated with improved cognition. 475 
However, these results are difficult to interpret because the studies used a sub-optimal dose of the 476 
compound, were of short duration and had limited statistical power. Almost 500 participants per 477 
group is needed to provide reasonable power to detect changes in standard neuropsychology 478 
measures in an RCT in individuals with mild-moderate AD11. For GLP analogues, only very small 479 
preliminary studies have been performed, although the results of these studies are encouraging. The 480 
only reported study of fasudil in individuals with MCI or AD showed good tolerability of the 481 
compound, but was too small to allow conclusions to be drawn about the effect of the treatment on 482 
cognition. No RCTs of anti-viral drugs in individuals with MCI or AD were identified in our literature 483 
searches. Therefore, the prioritisation of these candidates was predominantly based on the 484 
preclinical evidence, but with support from clinical information for most of the compounds. 485 
 486 
[H2] Compounds not short-listed  487 
 
 
[H3] Disease-modifying agents for rheumatoid arthritis  488 
Although the anti-inflammatory action of disease-modifying agents for rheumatoid arthritis 489 
(DMARDs) could theoretically reduce neuroinflammation in individuals with AD, the preclinical 490 
evidence supporting their usefulness was very limited108. The main evidence in favour of DMARDs 491 
was from an epidemiological population-based study that found a reduction in dementia risk in 492 
individuals receiving DMARDs compared with individuals not receiving DMARDs; however, the 493 
reported survival curves showed that the reduction in incidence new-onset dementia among 494 
DMARD users compared with non-DMARD users was very small18. The study did not assess the effect 495 
of any single drug within the DMARD class, which is a limitation as these drugs vary widely in terms 496 
of pharmacological action, efficacy and tolerability. Furthermore, a placebo controlled RCT of 497 
DMARDs in individuals with AD had negative findings109. On the basis of this evidence, the Delphi 498 
consensus panel concluded that DMARDs should not be prioritised as candidates for clinical trials in 499 
individuals with AD.  500 
 501 
[H3] ACE inhibitors 502 
Some evidence from preclinical studies suggests that ACE inhibitors can protect against AD 503 
pathology, for example, in a transgenic mouse model of AD treatment with perindopril was 504 
associated with significantly reduced amyloid and tau burdens and levels of oxidative stress110. The 505 
clinical evidence in favour of ACE inhibitors was very weak. An open-label study in 113 individuals 506 
with AD111 showed no significant benefits of perindopril treatment. A 4-month randomised, double-507 
blind, placebo-controlled, pilot clinical trial of ramipril in 14 individuals with hypertension at risk of 508 
AD reported that compared with placebo, treatment with ramipril was not associated with an 509 
improvement in cognition or a reduction incerebrospinal fluid levels of Aβ1–42112. These poor 510 
preliminary clinical results led the panel to conclude that ACE inhibitors are not high-priority agents 511 
for repurposing as an AD treatment, although the cardiovascular and cerebrovascular benefits of 512 
these drugs might indirectly reduce the risk of AD. 513 
[H1] Transcriptional approaches  514 
 515 
Above, we have prioritised drugs on the basis of their established mechanisms of action. Strategies 516 
for identifying novel compounds for preclinical testing and clinical trials include transcriptional 517 
profiling, which could also be applied to the identification of drugs for repurposing. Disease or injury 518 
can perturb gene expression in a characteristic manner in a specific tissue, creating a ‘transcriptional 519 
signature’. If a drug perturbs gene expression in an opposing manner to the disease or injury, it 520 
 
 
might have therapeutic effects. Therefore, assessing the transcriptional changes induced by libraries 521 
of compounds could provide an important way of identifying novel candidates for repurposing. The 522 
Broad Institute Connectivity Map (CMAP) collated the transcriptional signatures induced by 1,300 523 
drug-like compounds when applied to three cancer cell lines; importantly the CMAP data reflect 524 
responses specific to the known targets of the compounds as well as off-target responses113. The 525 
CMAP has been complemented by the LINCS L1000 project, which profiled the changes in 1,000 526 
‘landmark’ transcripts induced by different compounds and used algorithms to predict the likely 527 
changes in expression levels of the non-measured transcripts to generate a full transcriptional 528 
signature114. The LINCS L1000 program has generated a database of transcriptional signatures for 529 
~20,000 compounds, ~300 biologics, and shRNA and/or cDNA against ~5,000 genes in ~100 human 530 
cell lines, including iPSC-derived cortical neurons. The same approach could be applied to other 531 
compound libraries. 532 
 533 
Transcriptional profiles are widely available for early, middle and late stages of AD and other 534 
dementias115 and for almost all of the interventions, including genetic modifications, that are used to 535 
generate animal models of these diseases115-116. However, these data come from a variety of 536 
platforms and are hosted in different databases. The searchable, platform-independent expression 537 
database (SPIED) was developed to facilitate meta-analysis, with the aim of identifying disease-538 
associated transcriptional perturbations that are common to multiple datasets, including data from 539 
AD post-mortem samples117-118. This approach has identified shared transcriptional changes within 540 
multiple, independent AD-associated transcriptional signatures and the transcriptional signatures 541 
associated with other neurodegenerative diseases115. When the AD transcriptional signature was 542 
probed in CMAP, 153 drugs that perturb the cancer cell transcriptome in an opposing manner were 543 
identified115. Importantly, transcriptional changes that oppose those comprising the AD 544 
transcriptional signature were also observed when many of these drugs were applied to human 545 
iPSC-derived cortical neurons20. In a further study, transcriptional signatures for early and mild AD 546 
were used to probe both the CMAP and LINCS L1000 data, and 78 drugs with a significant inverse 547 
correlation were identified and screened using 6 independent in vitro assays that are designed to 548 
mimic various aspects of AD pathology119. Of these 78 agents, 19 significantly reduced the AD-549 
associated changes in in at least two assays, and 8 of these 19 agents were novel candidates known 550 
or likely to be brain penetrant. Some interesting candidates identified by this study included the 551 
adrenergic α-1 receptor antagonist doxasosin, the antibiotic thiostrepton, which is known to have 552 
proteasome inhibitor properties, and the histamine H2-receptor antagonist famotidine. In addition 553 
to the identification of novel candidates for repositioning, the work supports the hypothesis that 554 
transcriptional profiling could be an effective way of identifying or triaging compounds for in vitro 555 
 
 
screening. For example, other hits included drugs already considered to be repositioning candidates 556 
in AD, such as metformin, nabumetone and several flavonoids119. 557 
 558 
 559 
[H1] Future directions 560 
The global transcriptional signatures discussed in the previous section were generated without 561 
considering the functions of the individual transcripts or the known mechanisms of drug action. 562 
Therefore, this process is a ’black-box’ approach that operates independently of any mechanism-563 
based hypothesis. Almost 30 risk genes for AD have now been detected120 and the identification of 564 
drugs that alter the expression of some of these genes, or the expression of another gene with 565 
known therapeutic potential, would enable a hypothesis-driven approach to drug repositioning. 566 
There are no well-developed examples of this approach in the AD field, but we briefly discuss three 567 
examples from related diseases that highlight the promise of this ‘targeted’ repurposing approach. 568 
 569 
Accumulation of glutamate at synapses results in neuronal loss via ‘excitotoxicity’ and this process 570 
has been implicated as a causative mechanism in both acute brain injury and chronic 571 
neurodegenerative diseases such as AD121. Glutamate accumulation can result from the loss or 572 
failure of transporters that recycle this neurotransmitter, and reduced levels of the astrocyte 573 
glutamate transporter GLT1 (as known as EAAT2) is a characteristic feature of amyotrophic lateral 574 
sclerosis (ALS)122. In a milestone paper, Rothstein et al. postulated that drugs that increase the 575 
expression of GLT1 would be neuroprotective in a range of conditions, including ALS123. To test this 576 
hypothesis, the authors used neuronal cultures to screen 1,040 FDA-approved drugs and nutritionals 577 
and identified agents that increased levels of GLT1. The surprising finding was that the application of 578 
β-lactam antibiotics to neuronal cultures at concentrations similar to those in the brains of 579 
individuals being treated with these antibiotics increased GLT1 levels via a transcriptional 580 
mechanism. Moreover, treatment with the β-lactam ceftriaxone was associated with delayed 581 
neuronal loss and increased lifespan in a mouse model of ALS124. Beneficial effects of ceftriaxone 582 
have been reported in a wide range of nonclinical studies of pathologies that involve excitotoxicity, 583 
including models of AD124. Only one phase III clinical trial has tested the effects of ceftriaxone in 584 
neurodegenerative disease. The study cohort consisted of individuals with ALS and no significant 585 
difference in survival or functional decline (both primary endpoints) between the group of 586 
participants receiving ceftriaxone and the group of participants receiving placebo was detected125. 587 
Nonetheless, these findings are a useful example of a targeted repurposing approach and suggest 588 




As opposed to increasing the expression of a protective gene, other researchers have sought to 591 
identify drugs that can reduce the expression of a risk gene. This strategy was recently applied to the 592 
search for Parkinson disease (PD) therapies. Reducing α-synuclein transcription might be protective 593 
against PD126 and a biological screen of FDA-approved drugs showed that α2-adrenergic agonists, 594 
such as salbutamol, suppress α-synuclein transcription127. Moreover, in a preclinical rodent model of 595 
PD, salbutamol was associated with some protection against pathology and motor deficits, and 596 
analysis of clinical records showed that the risk of developing PD was lower in individuals treated 597 
with salbutamol than in individuals not treated with the drug127. This association was confirmed in 598 
an independent patient cohort128; however, other researchers have suggested that the association 599 
might in part arise from the use of salbutamol to treat smoking-related pulmonary disease, which 600 
means that the cohort treated with salbutamol are likely to already have a reduced risk of 601 
developing PD as a result of nicotine exposure129. Future clinical trials will be needed to establish the 602 
effects of salbutamol on PD, but nonetheless similar approaches could be used to identify 603 
compounds that reduce the expression of AD risk genes. 604 
  605 
Boosting levels of endogenous growth factors is another potential therapeutic approach that has 606 
been poorly explored in AD, but might be feasible, as shown by several studies in the field of PD130-607 
134. Recombinant human fibroblast growth factor 20 (FGF20) can limit neuronal loss in preclinical 608 
models of PD130,131; however, delivery and target engagement of growth factors remains a challenge 609 
in the clinical setting132. Endogenous FGF20 is enriched in the nigrostriatal pathway 133 and a simple 610 
in silico interrogation of CMAP identified 50 FDA-approved drugs that increase FGF20 transcript 611 
levels in cancer cell lines, 16 of which had transcriptional profiles that suggest they might be 612 
beneficial in PD134. Salbutamol and triflusal were in included in these 16 promising candidates and 613 
were then tested in vivo. In the 6-hydroxydopamine rat model of PD, treatment with either 614 
salbutamol or triflusal was associated with elevated levels of endogenous FGF20 in the nigrostriatal 615 
tract and a degree of neuroprotection. Evidence for salbutamol protecting humans against PD was 616 
discussed in the previous paragraph. Triflusal is a trifluoromethyl derivative of acetylsalicylic acid 617 
that inhibits platelet aggregation and, thereby, reduces risk of stroke135. The drug also has anti-618 
inflammatory, anti-excitotoxicity, and anti-Zn2+-toxicity effects that might limit ischemic brain 619 
damage136. 620 
  621 
Limitations of the targeted repurposing approach include the fact that a drug is likely to alter the 622 
expression of perhaps hundreds of transcripts. For example, whether salbutamol is neuroprotective 623 
because it reduces α-synuclein expression, increases FGF20 expression, acts via a third unknown 624 
mechanism, or acts via a combination of multiple mechanisms is not clear. Likewise, triflusal could 625 
 
 
be neuroprotective in PD because it elevates FGF20 and/or because it has antioxidant and anti-626 
inflammatory properties and/or because it acts via other unknown mechanisms. Similarly, although 627 
the parsimonious explanation for the neuroprotective properties of β-lactam antibiotics is an 628 
increase in glutamate uptake123, these drugs also have antioxidant and metal chelating properties 629 
that might explain or contribute to their efficacy as neuroprotective drugs124. This targeted 630 
repurposing approach is still in its infancy — transcriptional profiles have been successful in 631 
predicting some effects of compounds in vitro and in vivo, but it will be several years before we have 632 
any proof-of-concept clinical trials or examples of clinically available treatments. Nonetheless, the 633 
hypothesis-driven nature of targeted repurposing facilitates the design of experiments to directly 634 
test postulated mechanism of action of a specific compound. 635 
 636 
[H1] Conclusions 637 
Drug repositioning or repurposing offers an attractive and cost-effective approach that can 638 
complement traditional drug development. We used a Delphi consensus process to identify 639 
promising classes of compound for repurposing that we feel merit evaluation in clinical trials. GLP1 640 
analogues were identified as priority compounds in a Delphi consensus in 20129, but in this Review 641 
we discussed further supportive evidence that has subsequently emerged. We also presented and 642 
discussed three new compounds or classes of compound that were prioritised by the new Delphi 643 
consensus process. These compounds include the ROCK2 inhibitor fasudil, the cholinesterase 644 
inhibitor phenserine, which also has novel anti-apoptotic properties, and the anti-viral drugs 645 
aciclovir, valaciclovir and famciclovir. We also reviewed the evidence for a novel transcriptomic 646 
approach to drug repurposing that could substantially increase the scale of identification of 647 
candidate compounds. 648 
 649 
The potential advantages of complementing traditional drug discovery approaches with drug 650 
repositioning or repurposing include reduced costs and faster approval. However, several challenges 651 
to the expansion of this field remain, including the need for novel methodologies to identify and 652 
screen new candidates, for example, transcriptomic approaches. Creating and expanding funding 653 
streams to prioritise this work and providing better commercial incentives for repurposing, perhaps 654 
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Searches were performed in EMBASE, PsycINFO, MEDLINE and Cochrane databases for papers 692 
published after 1960. Search terms were as follows: Generic class OR specific drug names OR any 693 
known alternative name (obtained from the electronic Medicines Compendium and the British 694 
National Formulary) AND Dement* OR Alzheim* OR Mild Cognitive Impairmen* OR Neuropsych* 695 
test* OR cognitive func*. 696 
Key points  697 
• Drug repositioning and re-purposing offers a valuable alternative route for the identification 698 
of effective disease-modifying treatments for Alzheimer Disease. 699 
• The Delphi method can be used to bring together the opinion of multiple experts to suggest 700 
candidates for repurposing. 701 
• An expert Delphi consensus published in 2012 prioritised five compounds for repurposing as 702 
treatments for AD, of which glucagon-like-peptide analogues remain high priority 703 
candidates. 704 
•  A Delphi consensus involving the authors of this Review was conducted in 2018–2019 and 705 
identified the ROCK inhibitor fasudil, the cholinesterase inhibitor phenserine, and antiviral 706 
treatments such as valacycylovir as high priority candidates for trials in individuals with AD. 707 
• The prioritisation of these compounds was supported by strong packages of preclinical data, 708 
most of which include evidence from a number of different preclinical models.  709 
• Transcriptional screening approaches offer a novel means of identifying potential treatment 710 
candidates by targeting AD-associated transcriptional profiles. 711 
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Table 1: Priority candidates from the 2018–2019 Delphi consensus  1198 
Drug 
classes  
Proposed candidates Proposed mechanism 
of action  





Fasudil Reduction of Aβ levels 








Strong and consistent 
evidence of synaptic 
protection, reduction 
of amyloid and 
cognitive benefits in a 
range of in vivo animal 
models of AD71-73. 
Several studies have 
shown acceptable 




disease 75,137,138. Only 
one very small study 
in MCI and AD, which 
found  better scores 
on the verbal fluency  
test, mini-mental state 
exam and activities of 
daily living , with 
fasudil treatment than 
nimodipine; the full 
A well-powered RCT 
among participants with 
AD or MCI is needed to 
evaluate the effect on 




study has not been 
published in English76 
AChE 
inhibitors 






reduction in Aβ levels; 
increase in production 
of BDNF; inhibition of 
APP and α-synuclein 
synthesis; and anti-
apoptosis action on 
re-programmed cell 
death pathway19.  
Several preclinical 
studies showed that 
phenserine reduces 
APP levels in cultured 
cells and in the brains 
of animal models84-88; 
phase II studies of 
phenserine showed 
good tolerability and 
demonstrated some 
indication of cognitive 




cognitive function79.  
Further studies are needed 
to verify the potential 
mechanism of action in 
humans; these studies 
need to have adequate 







In vitro evidence 







anti-viral drugs might 
mitigate these effects.
A post-mortem case–
control study in 
carriers of APOE ε4 
found that AD was 
more common among 
individuals who had 
HSV compared with 
individuals who did 
not have HSV96; An 
epidemiological study 
also showed that a 
cohort of persons with 
HSV  had a higher risk 
of developing 
dementia than those 
without HSV105; recent 
large-scale studies 
suggest that the 
association between 
HSV and dementia is 
mitigated or reversed 
by anti-viral therapy 
95,105. 
At least two small RCTs in 
a combined total of 163 
individuals with AD are in 
progress 139,140, but a well-













of this class of agents 
might be a potential 
mechanism of action, 
but this has not been 




study found that 
participants using 
DMARDs had a 
modestly reduced risk 
of dementia than 
participants not using 
DMARDs18; a double-
blind RCT in 168 
individuals with mild 
AD over 18 months 
showed that 
hydroxychloroquine 
did not prevent 
More robust preclinical 
studies are needed to 
establish mechanism of 
action; high-powered RCTs 
are also needed to confirm 
findings from 






placebo; an open-label 
trial in 10 individuals 
with AD treated with 
hydroxychloroquine 
showed that CSF levels 









Reduction of amyloid 
deposition and tau 
hyperphosphrylation 
142; protection against 
oxidative stress 110,143 ; 
reduction of blood 
pressure. 
Evidence of benefit 
inconsistent across 
studies 144   




is fairly weak. RCTs, 
several of which are 
already ongoing, are 
needed to distinguish 
between the effect of 
hypertension control and 
the specific effects of ACE 
inhibitors. 
Abbreviations: ACE : angiontensin converting enzyme; AChE acetylcholinesterase; AD: Alzheimer’s 1199 
disease; ARBs: angiotensin receptor blockers; BDNF: brain-derived neurotrophic factor; COX-2 1200 
inhibitors: cyclo-oxygenase-2 inhibitors; DMARD- disease modifying antirheumatic drugs; MCI: mild 1201 
cognitive impairment; NSAIDS: non-steroidal anti-inflammatory drugs; RCTS-randomised clinical 1202 
trials; ROCK inhibitor: rho kinase inhibitor  1203 
 1204 





Box 1: Potential reasons for high rates of failure in RCTs of disease-modifying therapies for AD 1208 
Therapeutics and targets  1209 
• The vast majority of trials have focused on amyloid targets, resulting in a lack of breadth 1210 
• There is uncertainty regarding the specific disease mechanisms related to different amyloid 1211 
species  1212 
• Some therapeutics show poor brain penetration 1213 
• Reducing amyloid deposition alone might not be sufficient to induce disease-modifying 1214 
changes 1215 
• There has been only limited use of target engagement biomarkers in phase II studies to 1216 
inform phase III studies  1217 
Trial design  1218 
• Many trials might be performed in individuals with AD that has progressed too far to 1219 
therapies to have a disease-modifying effect. An increased focus on preclinical AD and at-risk 1220 
groups has been seen in more recent trials  1221 
• The results of phase II trials have been interpreted in an overly-optimistic manner, leading to 1222 
the progression of some compounds to larger trials that might not have been warranted  1223 
• Populations that are appropriately enriched for core AD pathologies were only included in 1224 
more recent trials.  1225 
• The neuropsychology measures used in trials can have a poor sensitivity to change. This 1226 
insensitivity is a particular issue in phase II trials, which have usually been underpowered to 1227 
detect changes in neuropsychology and clinical outcomes. 1228 
 1229 
 1230 
Drug repositioning and repurposing can enhance traditional drug development efforts and could 1231 
accelerate the identification of new treatments. In this Review, Ballard and colleagues highlight 1232 
priority compounds for repurposing in Alzheimer disease.  1233 
 1234 
 1235 
